Literature DB >> 15889536

Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus.

Walid Basha1, Ryoko Kitagawa, Miho Uhara, Hiromi Imazu, Kouhei Uechi, Junji Tanaka.   

Abstract

The effect of geldanamycin (GA), a specific inhibitor of heat shock protein 90 (Hsp90), on gene expression and replication of human cytomegalovirus (HCMV) was studied in human embryonic lung (HEL) fibroblasts. Kinetic analysis indicated that GA delayed synthesis of major immediate early (MIE), early and late viral proteins, and blocked a second tier of the synthesis of these proteins that occurred in untreated cells after 48 h post-infection (pi). Moreover, when HCMV-infected HEL cells were maintained with medium containing 40 nM GA for 6 days, with medium changes at 2-day intervals, the virus yield was reduced to an undetectable level. On a molecular level, the cellular kinase Akt and the transcription factor NFkappaB were activated in HCMV-infected cells within 30 min pi. NFkappaB was shown to be essential for MIE gene expression. However, in GA-treated cells, activation of both Akt and NFkappaB was greatly inhibited. Because LY294002, an inhibitor of cellular phosphatidylinositol 3-kinase (PI3-K), also prohibited HCMV-mediated activation of Akt and NFkappaB and synthesis of the MIE proteins, PI3-K signalling was necessary for expressing the MIE genes. These results suggest that the inhibitory effect of GA on HCMV replication is primarily caused by the disruption of the PI3-K signalling pathway, leading to the activation of NFkappaB, which plays a crucial role in expression of the critical MIE genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889536     DOI: 10.1177/095632020501600206

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  23 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

Authors:  Ron Geller; Marco Vignuzzi; Raul Andino; Judith Frydman
Journal:  Genes Dev       Date:  2007-01-15       Impact factor: 11.361

3.  The co-chaperone BAG3 regulates Herpes Simplex Virus replication.

Authors:  Christos A Kyratsous; Saul J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

4.  Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.

Authors:  Xiaoping Sun; Elizabeth A Barlow; Shidong Ma; Stacy R Hagemeier; Sarah J Duellman; Richard R Burgess; Judy Tellam; Rajiv Khanna; Shannon C Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

Review 5.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

Review 6.  Broad action of Hsp90 as a host chaperone required for viral replication.

Authors:  Ron Geller; Shuhei Taguwa; Judith Frydman
Journal:  Biochim Biophys Acta       Date:  2011-12-02

7.  Hsp90 inhibitor reduces porcine circovirus 2 replication in the porcine monocytic line 3D4/31.

Authors:  Jie Liu; Xuliang Zhang; Chang Ma; Ping Jiang; Shifeng Yun
Journal:  Virus Genes       Date:  2016-08-24       Impact factor: 2.332

8.  Extracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Bryan P Toole; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-04-27       Impact factor: 6.166

9.  Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.

Authors:  Xiaoping Sun; Jillian A Bristol; Satoko Iwahori; Stacy R Hagemeier; Qiao Meng; Elizabeth A Barlow; Joyce D Fingeroth; Vera L Tarakanova; Robert F Kalejta; Shannon C Kenney
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

Review 10.  Proteostasis in Viral Infection: Unfolding the Complex Virus-Chaperone Interplay.

Authors:  Ranen Aviner; Judith Frydman
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.